



ASX Announcement

1 September 2020

Lapse of Unlisted Share Options

Invion Limited (ASX:IVX) wishes to advise that on 31 August 2020 18,171,743 unlisted share options with an exercise price of \$0.03 per option and an expiry date of 12 February 2023 lapsed, unexercised, following the retirement of Melanie Farris as director.

Investor enquiries

Managing Director & CEO, Craig Newton

T: +61 3 9081 6005

E: investor@inviongroup.com

Media enquires

Brendon Lau

T: 0409 341 613

E: brendon@vantagepointpartners.com.au

About Invion

Invion is a life-science company that is leading the global research and development of Photosoft™ technology for the treatment of a range of cancers. Invion holds the Australia and New Zealand license rights to the Photosoft™ technology. Research and clinical trials are funded by the technology licensor, RMW Cho Group Limited, via an R&D services agreement with the Company. Invion is listed on ASX (ASX:IVX). This announcement was approved for release by a Sub-Committee of the Board of Invion Limited. For further information please contact investor@inviongroup.com.

About Photodynamic Therapy (PDT)

Invion is developing Photosoft™ technology as an improved next generation Photodynamic Therapy. PDT uses non-toxic photosensitisers and visible light in combination with oxygen to produce cytotoxic-reactive oxygen that kills malignant cells, shuts down tumours and stimulates the immune system. A potential alternative to surgery, and in contrast to radiotherapy and chemotherapy which are mostly immunosuppressive, PDT causes acute inflammation, expression of heat-shock proteins, and invasion and infiltration of a tumour by leukocytes.

Invion Limited ABN 76 094 730 417

Level 4, 100 Albert Road, South Melbourne, VIC, 3205, Australia

P: +61 9692 7222 W: www.inviongroup.com